Previous 10 | Next 10 |
2023-05-22 17:30:42 ET Gainers: Movella Holdings ( MVLA ) +14% . Trevi Therapeutics ( TRVI ) +5% . QUALCOMM ( QCOM ) +5% . Galera Therapeutics ( GRTX ) +4% . LivePerson ( LPSN ) +4% . Losers: Guardant Health (...
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence PR Newswire Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean ch...
2023-05-11 18:42:09 ET Trevi Therapeutics, Inc. (TRVI) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Lisa Delfini – Chief Financial Officer Conference Call Parti...
2023-05-11 16:26:17 ET Trevi Therapeutics press release ( NASDAQ: TRVI ): Q1 GAAP EPS of -$0.06 beats by $0.01 . The Company ended the first quarter of 2023 with $111.3 million in cash, cash equivalents and marketable securities. For further details see: Trev...
Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update PR Newswire I nitiating three clinical studies in chronic cough indications later this year Received Notice of Allowance for key U.S. patent for the use of oral nalbuphin...
Trevi Therapeutics to Present at Upcoming Yale Innovation Summit 2023 PR Newswire Presentation to take place on June 1 from 10:30 a.m. to 12:00 p.m. EDT at the Yale School of Management NEW HAVEN, Conn. , May 9, 2023 /PRNewswire/ -- Trevi Ther...
Trevi Therapeutics to Report Q1 2023 Financial Results and Provide a Corporate Update on May 11, 2023 PR Newswire Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn. , May 4, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasd...
Trevi Therapeutics Announces Two Presentations on the Phase 2 CANAL Data at the ATS 2023 International Conference PR Newswire Dr. Toby Maher of the Keck School of Medicine will give oral presentations for both scientific abstracts on oral nalbuphine extended release for ch...
Trevi Therapeutics to Participate in Upcoming May Investor Events PR Newswire 2023 Aegis Virtual Conference, May 2-4 American Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20 Yale Innovation Summit, May 31-June 1 ...
2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events PR Newswire Two abstracts accepted for oral presentation at the 13 th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutic...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...